United Therapeutics Corporation Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax
United Therapeutics Corporation (UTHR) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax of $900.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax · last filed 2018-02-21
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for the quarter ending 2014-12-31 was $361.00K, a 10.64% decline year-over-year.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for the quarter ending 2014-09-30 was $361.00K, a 11.08% decline year-over-year.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for the quarter ending 2014-06-30 was $361.00K, a 11.08% decline year-over-year.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for the quarter ending 2014-03-31 was $361.00K, a 11.08% decline year-over-year.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for fiscal 2017 was $900.00K, a 10.00% decline from fiscal 2016.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for fiscal 2016 was $1.00M, a 28.57% decline from fiscal 2015.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for fiscal 2015 was $1.40M, a 3.05% decline from fiscal 2014.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, reclassification adjustment from aoci, before tax for fiscal 2014 was $1.44M, a 10.92% decline from fiscal 2013.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax 12 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | $900.00K 10-K · filed 2018-02-21 | ||||
| 2016-12-31 | $1.00M 10-K · filed 2018-02-21 | ||||
| 2015-12-31 | $1.40M 10-K · filed 2017-02-22 | $1.39M 10-K · filed 2016-02-25 | |||
| 2014-12-31 | $361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $722.00K derived: sum of 2 quarters · filed 2016-02-25 | $1.08M derived: sum of 3 quarters · filed 2016-02-25 | $1.44M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $361.00K 10-Q · filed 2014-10-28 | $722.00K derived: sum of 2 quarters · filed 2014-10-28 | $1.08M 10-Q · filed 2014-10-28 | $1.49M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2014-06-30 | $361.00K 10-Q · filed 2014-07-29 | $722.00K 10-Q · filed 2014-07-29 | $1.13M derived: sum of 3 quarters · filed 2015-02-24 | $1.53M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2014-03-31 | $361.00K 10-Q · filed 2014-04-29 | $765.00K derived: sum of 2 quarters · filed 2015-02-24 | $1.17M derived: sum of 3 quarters · filed 2015-02-24 | $1.58M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $810.00K derived: sum of 2 quarters · filed 2015-02-24 | $1.22M derived: sum of 3 quarters · filed 2015-02-24 | $1.62M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $406.00K 10-Q · filed 2014-10-28 | $812.00K derived: sum of 2 quarters · filed 2014-10-28 | $1.22M 10-Q · filed 2014-10-28 | ||
| 2013-06-30 | $406.00K 10-Q · filed 2014-07-29 | $811.00K 10-Q · filed 2014-07-29 | |||
| 2013-03-31 | $406.00K 10-Q · filed 2014-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |